14:00 CET

Oncopeptides Virtual Capital Markets Day

The Program

14.00 – 16.00 CET (8:00am-10am EST) November 30th, 2020


“Building a Fully Integrated Biotechnology Company”

  • Introduction and Strategy for Value Growth – Marty J Duvall, CEO Oncopeptides
  • Multiple Myeloma
    “Myeloma remains one of the largest unmet medical needs within hematology”
    o Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York
  • Relapsed refractory multiple myeloma and melflufen – clinical experience with melflufen – Panel discussion
    o Professor Paul Richardson, MD, Dana-Farber Cancer Institute, Boston
    o Associate Professor Maria-Victoria Mateos, MD, PhD, University Hospital, Salamanca
    Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides
  • The clinical development program for melflufen
    “Understanding how melflufen can help patients the most” – Jakob Lindberg, CSO Oncopeptides
  • Successfully making the drug available for patients in the US
    Overview of US launch of melflufen – Marty J Duvall, CEO Oncopeptides
  • Questions and Answers


The CMD will be webcasted live on the link:https://tv.streamfabriken.com/oncopeptides-cmd-2020

Upcoming events

Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU

11:00 CET

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.

Annual General Meeting 2022

The Annual General Meeting in Oncopeptides AB (publ) will be held on Tuesday June 28, 2022, (changed from May 19, 2022) in Stockholm, Sweden. Due to the extraordinary situation resulting from the covid-19 pandemic, Oncopeptides’ Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. Hence, the Annual General Meeting will be held without physical presence.

Silent Period


Silent Period


Silent Period


Year-end report 2022

08:00 CET